# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The four-year analysis showed superior progression-free survival (PFS) and improved tolerability for patients compared to a cur...
Pfizer's Phase 3 CROWN trial results show Lorbrena significantly outperforms Xalkori in treating ALK-positive advanced NSCLC.
New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year).
An unprecedented 60% of patients remain alive without disease progression after five yearsUpdated results show continued 81% re...
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recen...